RecruitingPhase 1NCT06414889
Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder
Studying Familial platelet disorder with associated myeloid malignancy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- M.D. Anderson Cancer Center
- Principal Investigator
- Chitra Hosing, M.DM.D. Anderson Cancer Center
- Intervention
- G-CSF (filgrastim or biosimilar)(drug)
- Enrollment
- 4 target
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2024 – 2027
Study locations (1)
- MD Anderson Cancer Center, Houston, Texas, United States
Collaborators
RUNX1 Foundation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06414889 on ClinicalTrials.govOther trials for Familial platelet disorder with associated myeloid malignancy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06261060Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet DisorderM.D. Anderson Cancer Center
- RECRUITINGNCT03854318Longitudinal Studies of Patient With FPDMMNational Human Genome Research Institute (NHGRI)
See all trials for Familial platelet disorder with associated myeloid malignancy →